MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.57
-1.47
-4.32%
After Hours: 32.57 0 0.00% 17:01 04/03 EDT
OPEN
33.74
PREV CLOSE
34.04
HIGH
34.42
LOW
31.65
VOLUME
361.80K
TURNOVER
--
52 WEEK HIGH
55.64
52 WEEK LOW
22.65
MARKET CAP
2.87B
P/E (TTM)
-33.7129
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FGEN stock price target is 62.71 with a high estimate of 85.00 and a low estimate of 38.00.

EPS

FGEN News

More
  • Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus
  • Insider Monkey · 03/27 19:52
  • Biotech stocks have held up better than the broader market and these five are potential winners
  • MarketWatch · 03/24 21:23
  • Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results
  • Simply Wall St. · 03/04 12:07
  • After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push
  • American City Business Journals · 03/03 22:50

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About FGEN

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
More

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.